Citigroup raises Travere Therapeutics price target to $70
Citigroup analyst Yigal Nochomovitz maintained a Buy rating on Travere Therapeutics (NASDAQ: TVTX) and raised the price target to $70 from $62, indicating a positive outlook for the stock.
*this image is generated using AI for illustrative purposes only.
Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on Travere Therapeutics (NASDAQ: TVTX) while raising the price target for the stock. The new price target stands at $70, an increase from the previous target of $62.
Rating and Target Details
The decision to upgrade the price target reflects a revised outlook on the company's valuation potential. The following table summarizes the revised ratings:
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $62 |
| New Price Target | $70 |
The revised target suggests a positive trajectory for the shares based on the firm's analysis.
What specific factors are driving the revised valuation potential for Travere Therapeutics?
How might this price target increase influence investor sentiment toward the biotech sector?
What upcoming clinical trial results or regulatory decisions could further impact Travere's stock performance?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
